Pain News and Research

Latest Pain News and Research

CatchMyPain App for patients suffering from chronic pain

Pain management as an independent medical field has been significantly growing during the last few decades. Doctors and clinics specialize in the treatment of pain in general and chronic pain specifically. These specialists often suggest using a pain diary to track the pain, see its development and adjust the treatment accordingly. CatchMyPain is an electronic version of such a pain diary and a great solution for patients suffering from chronic pain.

11 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Indulgences abound during the holidays—from family gatherings to parties with friends and even stockings stuffed with goodies from Santa. For children with diabetes, overindulging on the delicacies of the season could result in more than a stomach ache, it could mean a trip to the emergency room.

10 Dec 2013

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Avanir Pharmaceuticals, Inc. today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

10 Dec 2013

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

electroCore’s non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th).

10 Dec 2013

Private contractors who worked in conflict environments struggle from depression, PTSD

Private contractors who worked in Iraq, Afghanistan or other conflict environments over the past two years report suffering from post-traumatic stress disorder and depression more often than military personnel who served in recent conflicts, according to a new RAND Corporation study.

10 Dec 2013

Equations help explain key parameters of stents that combat artherosclerosis

Coronary heart disease accounts for 18% of deaths in the United States every year. The disease results from a blockage of one or more arteries that supply blood to the heart muscle.

9 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Study shows VEEG telemetry monitoring with early cessation of AED therapy is safe, effective

Patients with epilepsy often undergo evaluation by concurrent video and EEG monitoring (vEEG) for therapeutic planning, including possible epilepsy surgery. Seizures during monitoring increase the diagnostic yield and requires the withdrawal of anticonvulsant drugs (AEDs) to allow seizures to occur.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

JCB Laboratories installs Lighthouse monitoring system to improve patient safety

JCB Laboratories, experts in sterile compounded solutions, has set the standard for environmental monitoring with the installation of a continuous cleanroom monitoring system from Lighthouse Worldwide Solutions. The pharmacy's latest improvement is a proactive approach to federal legislation that will bring new regulatory oversight to the compounding industry.

6 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

Pain News and Research

Latest Pain News and Research

CatchMyPain App for patients suffering from chronic pain

GW Pharmaceuticals receives U.S. patent for treating glioma

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Navidea receives Fast Track designation for Lymphoseek injection

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

Private contractors who worked in conflict environments struggle from depression, PTSD

Equations help explain key parameters of stents that combat artherosclerosis

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Study shows VEEG telemetry monitoring with early cessation of AED therapy is safe, effective

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

JCB Laboratories installs Lighthouse monitoring system to improve patient safety

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Women with moderate to severe menstrual cramps may find relief in erectile dysfunction drugs

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Forensics and toxicology - Industry Focus eBook eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Pain News and Research

Latest Pain News and Research

Forensics and toxicology - Industry Focus eBook eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in